Shopping Cart
Remove All
Your shopping cart is currently empty
TGFβ1-IN-1 is an orally active TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrotic markers (α-SMA and fibronectin) and can be used for the study of cancer and autoimmune diseases.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | - | In Stock | |
| 5 mg | $113 | - | In Stock | |
| 10 mg | $189 | - | In Stock | |
| 25 mg | $378 | - | In Stock | |
| 50 mg | $619 | - | In Stock | |
| 100 mg | $993 | - | In Stock | |
| 200 mg | $1,330 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $126 | - | In Stock |
| Description | TGFβ1-IN-1 is an orally active TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrotic markers (α-SMA and fibronectin) and can be used for the study of cancer and autoimmune diseases. |
| In vitro | In HSCs (LX-2) cells, TGFβ1-IN-1 (20 μM; 24 or 72 hours) showed a survival rate of 77.5% and an inhibition rate of 30.3% for LX-2 cells. Additionally, it significantly inhibited the protein expression of fibronectin and α-SMA[1]. |
| In vivo | In the CCl4-induced liver fibrosis model of C57BL/6J mice, TGFβ1-IN-1 (15 or 30 mg/kg; oral administration; daily; 3 weeks) significantly prevented CCl4-induced liver injury and reduced liver weight factor, serum ALT, AST, CHO, and TG levels[1]. |
| Molecular Weight | 364.438 |
| Formula | C22H24N2O3 |
| Cas No. | 2348795-14-0 |
| Smiles | O=C(C=CC1=CC=C(OC)C=C1)NC2=CC=CC(=C2)C(=O)NC3CCCC3 |
| Color | White |
| Appearance | Solid |
| Storage | keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (219.52 mM), Sonification is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (9.06 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.